| Shing-lu Ma, MD | |
|
7370 N Palm Ave, Fresno, CA 93711-5782 | |
| (559) 228-4222 | |
| (559) 228-4299 |
| Full Name | Shing-lu Ma |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 18 Years |
| Location | 7370 N Palm Ave, Fresno, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154625044 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | A110398 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Community Regional Medical Center | Fresno, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Community Health Partners | 6608280268 | 414 |
News Archive
Saint Louis University research shows a new class of drugs may hold promise in treating brain chemical problems such as Alzheimer's disease, says the principal investigator of research published in an early on-line version of Peptides.
Memorial Sloan Kettering Cancer Center introduced a new, consumer-friendly web presence for www.mskcc.org (Memorial Sloan Kettering Cancer Center) and www.sloankettering.edu (Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center), featuring an innovative platform and on-demand navigation for patients, caregivers, researchers, healthcare professionals, and graduate students, among other core audiences.
Dendreon Corporation today announced that the U.S. Food and Drug Administration has approved PROVENGE (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer.
Peripheral artery disease (PAD) affects 5 million individuals in the U.S. and is the leading cause of limb amputations. Doctors have long considered exercise to be the single best therapy for PAD, and now a new study helps explain why. Led by researchers at Beth Israel Deaconess Medical Center and published in this week's Online Early Edition of the Proceedings of the National Academy of Sciences (PNAS), the findings demonstrate that a protein called PGC-1alpha plays a key role in the process.
› Verified 1 days ago
| Entity Name | Community Foundation Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811258510 PECOS PAC ID: 0345406294 Enrollment ID: O20120723000387 |
News Archive
Saint Louis University research shows a new class of drugs may hold promise in treating brain chemical problems such as Alzheimer's disease, says the principal investigator of research published in an early on-line version of Peptides.
Memorial Sloan Kettering Cancer Center introduced a new, consumer-friendly web presence for www.mskcc.org (Memorial Sloan Kettering Cancer Center) and www.sloankettering.edu (Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center), featuring an innovative platform and on-demand navigation for patients, caregivers, researchers, healthcare professionals, and graduate students, among other core audiences.
Dendreon Corporation today announced that the U.S. Food and Drug Administration has approved PROVENGE (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer.
Peripheral artery disease (PAD) affects 5 million individuals in the U.S. and is the leading cause of limb amputations. Doctors have long considered exercise to be the single best therapy for PAD, and now a new study helps explain why. Led by researchers at Beth Israel Deaconess Medical Center and published in this week's Online Early Edition of the Proceedings of the National Academy of Sciences (PNAS), the findings demonstrate that a protein called PGC-1alpha plays a key role in the process.
› Verified 1 days ago
| Entity Name | Community Health Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952912420 PECOS PAC ID: 6608280268 Enrollment ID: O20210122001714 |
News Archive
Saint Louis University research shows a new class of drugs may hold promise in treating brain chemical problems such as Alzheimer's disease, says the principal investigator of research published in an early on-line version of Peptides.
Memorial Sloan Kettering Cancer Center introduced a new, consumer-friendly web presence for www.mskcc.org (Memorial Sloan Kettering Cancer Center) and www.sloankettering.edu (Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center), featuring an innovative platform and on-demand navigation for patients, caregivers, researchers, healthcare professionals, and graduate students, among other core audiences.
Dendreon Corporation today announced that the U.S. Food and Drug Administration has approved PROVENGE (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer.
Peripheral artery disease (PAD) affects 5 million individuals in the U.S. and is the leading cause of limb amputations. Doctors have long considered exercise to be the single best therapy for PAD, and now a new study helps explain why. Led by researchers at Beth Israel Deaconess Medical Center and published in this week's Online Early Edition of the Proceedings of the National Academy of Sciences (PNAS), the findings demonstrate that a protein called PGC-1alpha plays a key role in the process.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shing-lu Ma, MD 7370 N Palm Ave, Fresno, CA 93711-5782 Ph: () - | Shing-lu Ma, MD 7370 N Palm Ave, Fresno, CA 93711-5782 Ph: (559) 228-4222 |
News Archive
Saint Louis University research shows a new class of drugs may hold promise in treating brain chemical problems such as Alzheimer's disease, says the principal investigator of research published in an early on-line version of Peptides.
Memorial Sloan Kettering Cancer Center introduced a new, consumer-friendly web presence for www.mskcc.org (Memorial Sloan Kettering Cancer Center) and www.sloankettering.edu (Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center), featuring an innovative platform and on-demand navigation for patients, caregivers, researchers, healthcare professionals, and graduate students, among other core audiences.
Dendreon Corporation today announced that the U.S. Food and Drug Administration has approved PROVENGE (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer.
Peripheral artery disease (PAD) affects 5 million individuals in the U.S. and is the leading cause of limb amputations. Doctors have long considered exercise to be the single best therapy for PAD, and now a new study helps explain why. Led by researchers at Beth Israel Deaconess Medical Center and published in this week's Online Early Edition of the Proceedings of the National Academy of Sciences (PNAS), the findings demonstrate that a protein called PGC-1alpha plays a key role in the process.
› Verified 1 days ago
Dr. Gloria Patricia Jimenez, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2615 E Clinton Ave, Fresno, CA 93703 Phone: 559-225-6100 Fax: 559-241-6484 | |
Dr. Amreet K. Aujla, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 1187 E Herndon Ave Ste 101, Fresno, CA 93720 Phone: 559-440-0450 | |
Kenneth K. Latt, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 7300 N Fresno St, Fresno, CA 93720 Phone: 559-448-4500 | |
Dr. Pardeep Singh Bhullar, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 7370 N Palm Ave Ste 101, Fresno, CA 93711 Phone: 559-696-8046 | |
Lin Li, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2823 Fresno St, Fresno, CA 93721 Phone: 559-459-4390 | |
Albert T. Wilburn, MD Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 7300 N Fresno St, Fresno, CA 93720 Phone: 559-448-4500 | |
Anand K. Nagrani, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 7300 N Fresno St, Fresno, CA 93720 Phone: 559-448-4500 |